Alerts
Other content recommended for you
- Exploring the cost-effectiveness of EBV vaccination to prevent multiple sclerosis in an Australian setting
- Is there a nocebo response that results from disease awareness campaigns and advertising in Australia, and can this effect be mitigated?
- Public perceptions and behaviours related to the risk of infection with Aedes mosquito-borne diseases: a cross-sectional study in Southeastern France
- Decreased T cell reactivity to Epstein–Barr virus infected lymphoblastoid cell lines in multiple sclerosis
- Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage
- Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review
- Zika virus infection in the returning traveller: what every neurologist should know
- Epstein–Barr virus and multiple sclerosis
- Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis
- Serum IgG levels to Epstein-Barr and measles viruses in patients with multiple sclerosis during natalizumab and interferon beta treatment